Editas Medicine
Clinical-stage genome editing company developing transformative genomic medicines using CRISPR technology to treat patients with serious genetic diseases.
Notes
Editas Medicine is a clinical-stage genome editing company headquartered in Cambridge, Massachusetts. The company was founded to translate CRISPR gene editing technology into a new class of genomic medicines capable of treating serious genetic diseases.
Editas has developed both in vivo and ex vivo genome editing approaches, with programs targeting genetic diseases affecting the eye, liver, and blood. The company has exclusive licenses to foundational CRISPR intellectual property and has built a comprehensive genome editing platform.
Editas is publicly traded on NASDAQ under the ticker EDIT.
Team
- Gilmore O'Neill, M.D. - President & CEO
- Mark S. Shearman, Ph.D. - Chief Scientific Officer
- Michelle Robertson - Chief Financial Officer
Additional Research Findings
- Founded in 2013
- Publicly traded: NASDAQ (EDIT)
- Co-founded by CRISPR pioneers including Feng Zhang (Broad Institute), George Church (Harvard), Jennifer Doudna (UC Berkeley)
- Backed by Third Rock Ventures, Flagship Pioneering, and others
- Exclusive licenses to foundational CRISPR patents
- Lead programs in genetic eye diseases (Leber Congenital Amaurosis)
- Partnership with Bristol Myers Squibb for oncology applications
- In vivo and ex vivo gene editing approaches
- Headquarters in Cambridge, Massachusetts
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Third Rock Ventures | Boston, Massachusetts, USA | biotech-focused | seedseries-a+2 | 4 |